Renal tubular transport inhibitors are a class of drugs that interfere with the function of specific transporters in the renal proximal tubules, affecting the excretion and reabsorption of various substances, including drugs and endogenous compounds. These inhibitors target membrane transport proteins expressed in kidney tubule epithelial cells, which play a crucial role in drug elimination and can significantly influence drug pharmacokinetics. By modulating the activity of transporters such as organic anion transporters (OATs), organic cation transporters (OCTs), and multidrug and toxin extrusion proteins (MATEs), these inhibitors can alter the renal clearance of drugs, potentially leading to clinically significant drug-drug interactions (DDIs) and changes in drug efficacy or toxicity. Renal tubular transport inhibitors have both therapeutic applications, such as enhancing the efficacy of certain medications or reducing drug-induced nephrotoxicity, and potential risks, including unwanted drug accumulation and altered pharmacokinetics of co-administered drugs.
Targeted transporters.
The main transporter proteins targeted by renal tubular transport inhibitors are:
Organic anion transporters.
Organic anion transporters (OATs) are primarily expressed on the basolateral membrane of renal tubular cells and are responsible for the uptake of anionic drugs from the blood into the cells. OAT1 and OAT3 are the major OATs involved in drug transport in the kidney. OAT4 is located on the apical membrane, it plays a role in both secretion and reabsorption of compounds.
Organic cation transporters.
Organic cation transporters (OCTs) are involved in the transport of cationic drugs across renal tubular cell membranes. OCT2 is located on the basolateral membrane and mediates the first step in organic cation secretion in the kidney.
Multidrug and toxin extrusion proteins.
Multidrug and toxin extrusion proteins (MATEs) are expressed on the apical membrane of renal tubular cells and are responsible for the efflux of some drugs into the urine. MATE1 and MATE2 transporters work in conjunction with OCT2 to facilitate the secretion of cationic drugs.
Approved drugs.
Examples of approved drugs that act as renal tubular transport inhibitors include:
These inhibitors can be used therapeutically to alter drug pharmacokinetics, reduce drug-induced nephrotoxicity, or treat specific conditions like hyperuricemia. However, they can also lead to clinically significant drug-drug interactions by affecting the renal clearance of other medications.
References.
 ;templatestyles src="Reflist/styles.css" / ;